세계의 고안압증 치료 시장 보고서(2025년)

Ocular hypertension treatment encompasses strategies aimed at managing and lowering elevated intraocular pressure (IOP) in individuals diagnosed with this condition. This treatment is crucial for safeguarding the optic nerve, preserving visual function, and maintaining overall ocular health.

The primary categories of ocular hypertension treatment involve addressing intraocular pressure and managing glaucoma. Intraocular hypertension specifically denotes heightened pressure within the eye, particularly in the fluid-filled anterior chamber. These treatments are delivered through oral, parenteral, and various other administration routes, distributed across hospital pharmacies, retail outlets, online platforms, and similar channels. The key end-users of ocular hypertension treatment include hospitals, specialized clinics, and related establishments.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The ocular hypertension treatment market research report is one of a series of new reports from The Business Research Company that provides ocular hypertension treatment market statistics, including the ocular hypertension treatment industry's global market size, regional shares, competitors with an ocular hypertension treatment market share, detailed ocular hypertension treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the ocular hypertension treatment industry. This ocular hypertension treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ocular hypertension treatment market size has grown steadily in recent years. It will grow from $5.37 billion in 2024 to $5.51 billion in 2025 at a compound annual growth rate (CAGR) of 2.6%. The growth in the historic period can be attributed to increased aging population, high incidence of glaucoma, advancements in diagnostic tools, awareness and screenings, lifestyle changes and urbanization.

The ocular hypertension treatment market size is expected to see steady growth in the next few years. It will grow to $6.46 billion in 2029 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising global healthcare expenditure, advancements in treatment modalities, increased emphasis on personalized medicine, integration of telehealth services, rising geriatric population. Major trends in the forecast period include patient-centric approaches, regulatory landscape impact, global market expansion, technological advancements in monitoring devices, integration of artificial intelligence (AI).

The forecast of 4.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of prostaglandin analogs and tonometry devices sourced from Germany and Japan, exacerbating out-of-pocket glaucoma management costs and delaying early detection of vision loss. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The escalating prevalence of glaucoma is anticipated to drive the expansion of the ocular hypertension treatment market. Glaucoma, a chronic eye ailment leading to potential vision impairment and blindness by damaging the optic nerve, has a direct link to ocular hypertension, contributing to a cluster of eye conditions causing lasting visual impairment. Projections from the BrightFocus Foundation Highlights in October 2022 indicated that globally, 80 million individuals were affected by glaucoma, with estimates predicting a surge to over 111 million by 2040. This projected rise in glaucoma instances substantiates the growth of the ocular hypertension treatment market.

The growth of the aging demographic is poised to fuel advancements in the ocular hypertension treatment market. As populations age due to declining birth rates and extended life expectancy, ocular hypertension becomes more prevalent. Heightened intraocular pressure risk elevates with age, underscoring the significance of regular eye screenings for early detection and management. Forecasts from the ARC Centre of Excellence in Population Ageing Research suggest Australia's 65-and-above population could grow to 6.66 million by 2041 from an estimated 4.31 million in 2021, marking a 54% increase. This demographic shift substantiates the expansion of the ocular hypertension treatment market.

Innovation stands as a prominent trend propelling the ocular hypertension treatment market. Companies within this sector are actively embracing novel technologies to fortify their market standing. For instance, in April 2022, Sandoz, a Switzerland-based generics and biosimilars manufacturer, introduced the Brimonidine tartrate/timolol maleate ophthalmic solution. This eye drop combination, available in generic forms of 0.2% or 0.5%, effectively reduces eye pressure in individuals with ocular hypertension. Fixed medication combinations offer patients simplicity, improved compliance, reduced exposure to preservatives, and potential cost savings.

Notable players in the ocular hypertension treatment market are forging strategic partnerships and collaborations to fortify their market presence. These alliances, formed to achieve specific business objectives, are gaining prominence. For instance, in July 2022, AbbVie Inc., a US-based pharmaceutical firm, announced a strategic collaboration with iSTAR Medical SA, a Belgian clinical-stage medical technology company, to advance and commercialize the MINIject device. This minimally invasive glaucoma surgical (MIGS) device, designed to reduce intraocular pressure in primary open-angle glaucoma patients, expands AbbVie's eye care portfolio. The collaboration aims to expedite the development and market availability of the MINIject device, offering a novel treatment avenue for glaucoma patients.

In November 2022, Alcon, a pharmaceutical and medical device company headquartered in the US, completed the acquisition of Aerie Pharmaceuticals Inc., a clinical-stage pharmaceutical firm based in the US, for an undisclosed amount. This strategic acquisition significantly enhances Alcon's portfolio of commercial offerings and bolsters its developmental pipeline within the ocular hypertension treatment market.

Major companies operating in the ocular hypertension treatment market include Angelini SpA, Laboratorios Sophia, Neurim Pharmaceuticals Ltd., Nicox SA, Novartis AG, AbbVie Inc., Alcon, Ocular Therapeutix Inc., Sylentis S.A, Taejoon Pharma Co. Ltd., Bausch Health Companies Inc., Merck & Co. Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Laboratorios Salvat SA, Shionogi & Co. Ltd., Otsuka Holdings Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Eisai Co. Ltd., Daiichi Sankyo Company Limited, Celgene Corporation, Boehringer Ingelheim International GmbH, SK Bioscience Co., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited

North America was the largest region in the ocular hypertension treatment market in 2024. The regions covered in the ocular hypertension treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ocular hypertension treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The ocular hypertension treatment market includes revenues earned by entities by providing carbonic anhydrase inhibitors, prostaglandins, and beta-blockers that are used to treat ocular hypertension. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ocular Hypertension Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ocular hypertension treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ocular hypertension treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ocular hypertension treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Intraocular Hypertension; Glaucoma
• 2) By Route of Administration: Oral; Parenteral; Other Routes
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channel
• 4) By End-Users: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Intraocular Hypertension: Beta Blockers; Prostaglandin Analogs; Carbonic Anhydrase Inhibitors; Alpha Agonists; Rho Kinase Inhibitors
• 2) By Glaucoma: Open-Angle Glaucoma Treatments; Angle-Closure Glaucoma Treatments; Secondary Glaucoma Treatments; Congenital Glaucoma Treatments; Combination Therapies
• Companies Mentioned: Angelini SpA; Laboratorios Sophia; Neurim Pharmaceuticals Ltd.; Nicox SA; Novartis AG; AbbVie Inc.; Alcon; Ocular Therapeutix Inc.; Sylentis S.A; Taejoon Pharma Co. Ltd.; Bausch Health Companies Inc.; Merck & Co. Inc.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Laboratorios Salvat SA; Shionogi & Co. Ltd.; Otsuka Holdings Co. Ltd.; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc.; Eisai Co. Ltd.; Daiichi Sankyo Company Limited; Celgene Corporation; Boehringer Ingelheim International GmbH; SK Bioscience Co.; Regeneron Pharmaceuticals Inc.; F. Hoffmann-La Roche AG; Sun Pharmaceutical Industries Ltd.; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ocular Hypertension Treatment Market Characteristics

3. Ocular Hypertension Treatment Market Trends And Strategies

4. Ocular Hypertension Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Ocular Hypertension Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Ocular Hypertension Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Ocular Hypertension Treatment Market Growth Rate Analysis
• 5.4. Global Ocular Hypertension Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Ocular Hypertension Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Ocular Hypertension Treatment Total Addressable Market (TAM)

6. Ocular Hypertension Treatment Market Segmentation

• 6.1. Global Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intraocular Hypertension
• Glaucoma
• 6.2. Global Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes
• 6.3. Global Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channel
• 6.4. Global Ocular Hypertension Treatment Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Others End-Users
• 6.5. Global Ocular Hypertension Treatment Market, Sub-Segmentation Of Intraocular Hypertension, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta Blockers
• Prostaglandin Analogs
• Carbonic Anhydrase Inhibitors
• Alpha Agonists
• Rho Kinase Inhibitors
• 6.6. Global Ocular Hypertension Treatment Market, Sub-Segmentation Of Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Open-Angle Glaucoma Treatments
• Angle-Closure Glaucoma Treatments
• Secondary Glaucoma Treatments
• Congenital Glaucoma Treatments
• Combination Therapies

7. Ocular Hypertension Treatment Market Regional And Country Analysis

• 7.1. Global Ocular Hypertension Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Ocular Hypertension Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ocular Hypertension Treatment Market

• 8.1. Asia-Pacific Ocular Hypertension Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ocular Hypertension Treatment Market

• 9.1. China Ocular Hypertension Treatment Market Overview
• 9.2. China Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ocular Hypertension Treatment Market

• 10.1. India Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ocular Hypertension Treatment Market

• 11.1. Japan Ocular Hypertension Treatment Market Overview
• 11.2. Japan Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ocular Hypertension Treatment Market

• 12.1. Australia Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ocular Hypertension Treatment Market

• 13.1. Indonesia Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ocular Hypertension Treatment Market

• 14.1. South Korea Ocular Hypertension Treatment Market Overview
• 14.2. South Korea Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ocular Hypertension Treatment Market

• 15.1. Western Europe Ocular Hypertension Treatment Market Overview
• 15.2. Western Europe Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ocular Hypertension Treatment Market

• 16.1. UK Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ocular Hypertension Treatment Market

• 17.1. Germany Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ocular Hypertension Treatment Market

• 18.1. France Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ocular Hypertension Treatment Market

• 19.1. Italy Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ocular Hypertension Treatment Market

• 20.1. Spain Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ocular Hypertension Treatment Market

• 21.1. Eastern Europe Ocular Hypertension Treatment Market Overview
• 21.2. Eastern Europe Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ocular Hypertension Treatment Market

• 22.1. Russia Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ocular Hypertension Treatment Market

• 23.1. North America Ocular Hypertension Treatment Market Overview
• 23.2. North America Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ocular Hypertension Treatment Market

• 24.1. USA Ocular Hypertension Treatment Market Overview
• 24.2. USA Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ocular Hypertension Treatment Market

• 25.1. Canada Ocular Hypertension Treatment Market Overview
• 25.2. Canada Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ocular Hypertension Treatment Market

• 26.1. South America Ocular Hypertension Treatment Market Overview
• 26.2. South America Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ocular Hypertension Treatment Market

• 27.1. Brazil Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ocular Hypertension Treatment Market

• 28.1. Middle East Ocular Hypertension Treatment Market Overview
• 28.2. Middle East Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ocular Hypertension Treatment Market

• 29.1. Africa Ocular Hypertension Treatment Market Overview
• 29.2. Africa Ocular Hypertension Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Ocular Hypertension Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Ocular Hypertension Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ocular Hypertension Treatment Market Competitive Landscape And Company Profiles

• 30.1. Ocular Hypertension Treatment Market Competitive Landscape
• 30.2. Ocular Hypertension Treatment Market Company Profiles
  • 30.2.1. Angelini SpA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Laboratorios Sophia Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Neurim Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Nicox SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Ocular Hypertension Treatment Market Other Major And Innovative Companies

• 31.1. AbbVie Inc.
• 31.2. Alcon
• 31.3. Ocular Therapeutix Inc.
• 31.4. Sylentis S.A
• 31.5. Taejoon Pharma Co. Ltd.
• 31.6. Bausch Health Companies Inc.
• 31.7. Merck & Co. Inc.
• 31.8. Pfizer Inc.
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Laboratorios Salvat SA
• 31.11. Shionogi & Co. Ltd.
• 31.12. Otsuka Holdings Co. Ltd.
• 31.13. Mitsubishi Tanabe Pharma Corporation
• 31.14. Astellas Pharma Inc.
• 31.15. Eisai Co. Ltd.

32. Global Ocular Hypertension Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ocular Hypertension Treatment Market

34. Recent Developments In The Ocular Hypertension Treatment Market

35. Ocular Hypertension Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Ocular Hypertension Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Ocular Hypertension Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Ocular Hypertension Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer